Tscan Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Tscan Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Tscan Therapeutics Inc
Rating: 1.45633325
Author: Trendlyne DVM scores

about

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and ...

1.64 -0.01 (-0.61%)

74.29% Fall from 52W High

146.2K

XNAS Volume

XNAS 08 Aug, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Tscan Therapeutics Inc is on 12 Aug 2025 for the purpose of TScan Therapeutics Inc Second Quarter Earnings Results for 2025 See details

Not Eligible

Expensive Valuation

19.8 / 100

Technically Neutral

38.4 / 100

1Yr Price target upside is 449%

7 analysts

Tscan Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Tscan Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and ...

74.29% Fall from 52W High

SWOT Analysis

Tscan Therapeutics Inc Live Price Chart